Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Arteris, Inc. director Claudia F. Munce received a grant of 860 shares of fully vested restricted common stock as part of her board retainer. The shares represent fees she chose to take in stock instead of cash, based on an average trading price of $15.98 for Arteris common stock between February 20, 2026 and April 2, 2026. After this compensation-related acquisition, she holds 101,711 shares directly. The filing notes she elected to defer the receipt of these shares.
Arteris, Inc. VP and Chief Financial Officer Nicholas B. Hawkins reported four open-market sales of common stock on April 2, 2026, totaling 4,870 shares at $17.6528 per share. According to the disclosure, these sales were executed under a mandatory “sell to cover” arrangement to fund tax withholding obligations arising from the release of restricted stock units, rather than discretionary trades. Following the final sale, Hawkins directly held 118,614 shares of Arteris common stock.
Arteris, Inc. Chief Operating Officer Laurent R. Moll reported multiple open-market sales of common stock primarily to cover taxes from the release of restricted stock units. He sold a total of 7,154 shares at prices between $17.65 and $18.23 per share and now directly holds 280,972 shares. According to the disclosure, these sales were required under the company’s equity plans as “sell to cover” transactions and were executed pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2025, indicating they were not discretionary trades.
Arteris, Inc. President and CEO Charles Janac reported tax-related stock sales. He sold a total of 20,809 shares of common stock in open-market transactions on April 2 and April 6, 2026 at weighted average prices of about $17.6528 and $18.3394 per share.
The company explains these sales were made solely to satisfy his tax liability from the release of restricted stock units under a mandated “sell to cover” feature of its equity incentive plans, and are not discretionary trades. The filing also notes the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2025.
After these trades, Janac holds 196,729 shares directly, plus indirect holdings of 9,189,071 shares through Bayview Legacy, LLC and 56,252 shares through the Charles and Lydia Janac Trust, where he has voting and dispositive authority.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported mandated sales of common stock to cover taxes from restricted stock unit vesting. On April 2, 2026, he sold a total of 3,649 shares at $17.6528 per share in open-market transactions.
The footnote explains these were "sell to cover" trades required under Arteris’ equity incentive plans to satisfy tax withholding obligations, and were not discretionary. After these sales, Alpern continues to hold 86,386 shares of Arteris common stock directly.
BAYVIEW LEGACY, LLC reported multiple 10b5-1 sales of Common stock. The transactions occurred between 01/08/2026 and 03/26/2026, with individual trades including 50,000 shares on 01/08/2026 for $829,155.00 and 41,000 shares on 03/09/2026 for $582,626.40. The filing also lists 11,800 Restricted Stock Units dated 04/01/2026.
Arteris, Inc. President and CEO Charles K. Janac, through Bayview Legacy, LLC, reported open-market sales of 40,000 shares of Arteris common stock on March 25–26, 2026 at weighted average prices of $18.0309 and $18.3458. These trades were executed under a Rule 10b5-1 trading plan adopted on March 5, 2025. Following the transactions, Bayview Legacy, LLC holds 9,189,071 shares indirectly, while separate holding entries show Janac with 217,538 shares held directly and 56,252 shares held through the Charles and Lydia Janac Trust.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported selling a total of 40,000 shares of Arteris common stock in two open-market transactions. On March 25, it sold 7,012 shares at a weighted average price of about $18.03 per share, followed by 32,988 shares on March 26 at a weighted average price of about $18.35 per share.
The sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025. After these transactions, Bayview Legacy, LLC indirectly holds 9,189,071 Arteris common shares, so the sale represents a small portion of its overall position.
AIP (Form 144): Notice to sell 20,000 shares of Common Stock. The filing lists a proposed sale of 20,000 common shares with an aggregate reported value of $359,800.00. The cover row references Morgan Stanley Smith Barney LLC Executive Financial Services and the listing 03/26/2026.
The excerpt also lists multiple recent 10b5-1 sales by BAYVIEW LEGACY, LLC and one sale by K. CHARLES JANAC across January–March 2026, showing executed transactions and proceeds for context.